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Conclusion 
This second workshop on hand osteoarthritis (OA), held in 
Boston, U.S.A. in May 1999, was most stimulating. Hand 
OA is a frequent, serious and crippling disease. Much still 
remains to be done with regard to the establishment of its 
diagnosis, clinical evaluation and treatment. The main 
objective of the meeting was to continue the dialogue 
initiated at the first workshop held in 1994, and to allow 
for constructive debate on the epidemiological, clinical, 
imaging and therapeutic aspects of research. A number 
of excellent presentations were made and intensive dis- 
cussions covering several major areas of clinical interest 
were held. 
Session 1: Epidemiology, genetics and risk 
factors 
The first session focused on epidemiology, genetics and 
risk factors. The most recent studies published on these 
topics were reviewed. They provided useful insight into the 
role of a number of factors involved in the ethiopathogen- 
esis and progression of the disease. The hand is a common 
site of peripheral joint involvement in OA. Although often 
underestimated as a cause of disability, it is also an 
important indicator of a systemic tendency to OA, which 
may involve weight-bearing joints such as hips and knees. 
There seems to be no obvious consensus at this time 
regarding the definition of hand OA and generalized OA. 
The topography of affected joints as well as the threshold 
number of affected joints used in defining generalized OA 
remain unidentified. The site and number of joints involved 
in fulfilling an accepted definition lacks clarity. Also remain- 
ing unclear is the role of symptoms versus structural 
changes. Such a definition is highly variable from one 
classification to another. Although the definition of hand 
OA, particularly for epidemiological studies, has undergone 
reassessment and revision over the last few years, it still 
remains a problem. A number of the existing classifications 
are confusing. The balance between criteria, including 
clinical symptoms, and anatomical X-ray changes remains 
to be determined. The inclusion or exclusion of metacar- 
pophalangeal (MCP) and carpometacarpal (CMC) joints 
vary from one classification to another and should be 
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standardized. There is still debate on whether the erosive 
form of hand OA should be considered a different disease. 
There was a general agreement hat the definition of hand 
OA should be made on population-based studies. 
A number of epidemiological studies suggest that 
genetic factors are likely to play an important role in the 
etiopathogenesis of hand OA. For instance, the greater 
concordance for hand OA in monozygotic than in dizygotic 
twins, and the substantial increase in the risk of hand OA in 
first-degree relatives of these patients provide a strong 
rationale for a search of the genes involved. The study of 
the role of genetic factors in this disease is complicated by 
many factors, including case definition, other risk factors, 
latence of phenotype expression, difficult access to other 
members of the family, as well as the absence of a valid 
definition of the disease per se. The ongoing work on 
the role of genetics in hand OA is most important and 
should soon provide new insights into the pathogenesis of 
hand OA. 
An agreement was reached on the most common risk 
factors associated with hand OA. These included age, 
gender, family, obesity and physical activity/trauma. Age is 
a well-known and strong risk factor, not only for hand OA 
but also for all joint sites. It is possible that some risk factors 
may act by bringing the development of OA forward rather 
than having specific mechanisms of causation or preven- 
tion. There was also an agreement that female gender 
results in a predisposition to OA at all sites except at the 
hip. The exact reasons remain unclear. Obesity is a strong 
risk factor for development of knee OA in women but its 
association with hand OA remains controversial, with 
the possible exception of an increased risk of first CMC 
joint OA. 
One important aspect of hand OA is that it often occurs in 
women around the time of menopause. However, the exact 
role of sex hormones in this disease is still a controversial 
issue. The possible influence of hormone replacement 
therapy (HRT) on the incidence and progression of hand 
OA is still uncertain. Hormone replacement therapy 
remains a likely protective risk factor based on studies for 
hip and knee OA. The data for hand OA are sparse. A large 
epidemiologic prospective cross-sectional study done on 
menopausal women with hand OA showed no differences 
in the characteristics of hand OA between patients who did 
not receive HRT, whatever the symptom activity. HRT did 
not seem to influence the severity or the symptom activity 
of hand OA. 
Physical activity/trauma seems to have only modest 
effects on the prevalence and incidence of hand OA. These 
factors may be of more importance in the first CMC joints 
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and on the dominant hand, on which there are greater 
mechanical forces. However, the question remains whether 
the very frequent symmetry of hand sites implies genetic or 
constitutional cause rather than mechanical factors. 
It was agreed that more studies were needed to achieve 
a more comprehensive understanding of all of the risk 
factors associated with hand OA. This seems true for 
almost all of the topics that have been under previous 
discussion. Recent studies have demonstrated the need for 
a better definition of the disease in order to make substan- 
tial progress in defining the role of genetic and 6ther factors 
in hand OA. Moreover, the criteria on which such a defini- 
tion will be based should be very clearly defined, whether 
they are to be anatomical, functional, symptom-based, etc. 
We also need to measure and quantify the symptoms and 
severity of the disease better. 
Session 2: Clinical aspects 
The workshop was'highly productive in reviewing several 
clinical aspects of hand OA. The importance of the clinical 
relevance of hand OA was stressed by study reports 
showing not only its very high prevalence, but also that 
a large number of these patients present substantial 
symptoms, which increase with age. 
Although very common, a disease such as hand OA has 
been the subject of a limited number of clinical trials aimed 
at determining the effectiveness of drug treatment on 
symptoms and/or progression of structural changes. This 
disease deserves to be the subject of further therapeutic 
trials. The demand for treatment is high, and it might not be 
possible to extrapolate results of trials from other joints 
such as hip and knee OA to hand OA, which often progress 
differently. Today there are a number of specific and sensi- 
tive tools and assessment methods that allow the hand to 
be considered a valuable 'model' to study treatments for 
OA. These tools and methods provide acceptable accuracy 
leading to conclusive results. Among the different tools 
available to study the impact of hand OA on patients' 
health, those exploring function are of particular impor- 
tance. Moreover, their sensitivity to assess changes over 
time would be of prime importance, particularly in the 
context of clinical study. For this purpose, both the func- 
tional index of hand OA (FIHOA) and the pain assessment 
on a visual analog scale (VAS) have been demonstrated 
through trials to be valid and useful. The wish was 
expressed that these different methodologies be validated 
through an international consensus meeting. 
Among the different risk factors associated with OA, 
mechanical factors seem to be of particular relevance to 
hand OA. A report presented at the workshop demon- 
strated that men with high maximal grip strength had an 
increased risk of OA in proximal interphalangeal (PIP), 
MCP and thumb-base joints. Women with high maximal 
grip strength had an increased risk of developing OA in 
MCP joints and a modest increase in risk for OA in the 
thumb base. No association was found between maximal 
grip strength and incident distal interphalangeal (DIP) OA in 
men or women. 
Although several studies have been conducted on epi- 
demiology, genetics, clinical and radiological presentations 
of hand OA, conversely, only a limited number of thera- 
peutic studies in hand OA were found. The existing pub- 
lished data on hand OA raises numerous questions and 
gives very few answers with regard to the evaluation of 
therapeutic agents mainly because of several method- 
ological limitations. Based on those findings a number of 
recommendations seems appropriate, including that a con- 
sensus needs to be reached on diagnosing hand OA, the 
definitions of the disease, its severity and symptom activity, 
and allowing for standardized selection of patients. Primary 
and secondary evaluation criteria with appropriate, vali- 
dated, reliable and sensitive tools need to be selected. 
Moreover, it would be preferable that the present widely 
accepted guidelines for the conduct of clinical trials in OA 
be adapted to the need for further specific studies in 
hand OA. 
Session 3: Imaging 
This session included three main parts: a review of the 
radiological assessment methods of hand OA, the scoring 
system of Verbruggen and Veys, and a special point-- 
how calcified cartilage advances into articular cartilage. 
For the moment, the best method for assessing the 
grade and progression of hand OA is standard radiography, 
provided it is performed separately for each hand. To date, 
only the posteroanterior frontal view has been used. The 
X-ray features should be graded separately to assess the 
extent and course of the disease, and not as a composite 
index. In hand OA, osteophyte size is the most sensitive 
indicator of progression in contrast to hip and knee OA, 
where it is the joint space narrowing (JSN). At the present 
time, and for long-term trials, either the Kallman or the 
Verbruggen-Veys grading system could be used. However, 
whether a combination of both these grading systems 
would be more reliable and relevant remains to be seen. 
Atlases were considered critically: a simple diagram of 
each X-ray feature of every grade of hand joints could 
become a more reliable tool than the existing radiographic 
atlases. 
The two scoring systems used to assess progression of 
hand OA were described in detail by Verbruggen and Veys, 
who conducted a three-year trial. The systems used were: 
(1) the anatomical lesion progression system in OA joints 
(osteophytes, JSN, subchrondral sclerosis) and (2) the 
anatomical phase system. The latter was able to track the 
erosive phase that was present or occurred in 40% of 
patients who were symptomatic at onset and for whom the 
lesion progression system was not designed and did not 
work--erosions prevent the interpretation of changes in 
JSN and in subchondral bone lesions. The erosive phase is 
followed by a predictable reparative phase. Another cri- 
terion was considered: occurrence of new OA X-ray signs 
in joints that were not involved at baseline. However, this 
was not observed during the three-year trial. 
Using macroradiographs, the advancement of the zone 
of calcified cartilage, termed a ZCC step, was seen in 64% 
of 44 hand OA patients and localized in the convex articular 
surface of half the hand joints. After 18 months, new ZCC 
steps had formed in about one-third of cases. However, the 
significance of this curious feature is unknown. These 
changes are tiny (<0.2 mm), are not associated with JS 
width reduction, and do not seem to be related to mechan- 
ical stress. The hypothesis of a vascular disturbance in 
microcirculation is debatable. 
Session 4: Therapeutic problems 
An important question raised during this session was 
whether the critical review of existing therapeutic trials in 
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hand OA allows avoidance of past flaws. Besides some 
classic shortcomings (e.g. definition of a primary assess- 
ment criterion), this session addressed some issues more 
specific to hand OA. (1) Should thumb root (CMC1) OA be 
assessed together with other joints in hand OA or separ- 
ately? (2) What is the minimal level of pain on VAS, the 
minimum number of painful joints, the minimal value of the 
functional index score for inclusion into a trial for a given 
patient? (3) What are the most reliable criteria of hand OA 
activity? (4) What is the best duration of a structure- 
modifying drug trial? More than 3 years? (5) What is the 
most reliable radiographic scoring system? A consensus is 
needed to provide answers to these questions. 
Some of the papers presented tried to rough out some 
solutions. Regarding diagnosis, additional items to the 
American College of Rheumatology (ACR) criteria are 
proposed, as well as a limited number of exclusion criteria. 
Likewise, with regard to the selection of patients, additional 
criteria are proposed in order to distinguish between 'active' 
and 'quiescent' hand OA. For example: VAS pain >30 ram, 
Dreiser's index score >5-6 points. Concerning efficacy 
assessment, the Dreiser functional index seems more 
accurate and sensitive to change when completed with the 
weekly self-assessment of joint pain. The other functional 
index for hand OA, termed AUSCAN, is not freely available. 
For structure-modifying drug trials, X-ray features of OA 
scored according to one of the existing methods are 
probably more reliable when conducted over three years, 
using strict inclusion criteria. Combining these results with 
symptoms is strongly desirable. 
The following issues concerning clinical trials are still 
awaiting answers and obviously indicate the need for more 
studies. Which functional index to use? Use daily or weekly 
questionnaires or tracking flares and their duration? Which 
scoring system is the best for long-term structure-modifying 
drug trials? And what does 'long-term' mean? How to 
choose between a 2 (minimal) or a 5 (maximal) year 
duration, or an intermediate span? We realize that the 
scientific requirements are endless. However, we have to 
start somewhere. 
